APOE and Alzheimer disease: Abnormal neurometabolites appear early in the AD process and occur within the spectrum of Alzheimer’s Disease, including early changes in APOE4 carriers; validation between AD biomarkers and APOE4 was reviewed by Piersson et al. [178].